Preclinical validation of salivary biomarkers for primary Sjögren's syndrome

摘要: Objective. Sjogren's syndrome (SS) is a systemic autoimmune disease with variety of presenting symptoms that may delay its diagnosis. We previously discovered number candidate salivary biomarkers for primary SS using both mass spectrometry and expression microarray analysis. In the current study, we aimed to verify these in independent patient populations evaluate their predictive values detection. Methods. total, 34 patients SS, lupus erythematosus (SLE), healthy individuals were enrolled validation studies. Salivary protein measured either Western blotting or enzyme-linked immunosorbent assay, messenger RNA (mRNA) quantitative polymerase chain reaction. Statistical analysis was performed R software, version 2.9. Results. Three (cathepsin D [CPD], alpha-enolase, beta(2)-microglobulin [beta(2)m]) 3 mRNA (myeloid cell nuclear differentiation antigen [MNDA], guanylate binding 2 [GBP-2], low-affinity IIIb receptor Fc fragment IgG) significantly elevated compared SLE controls. The combination biomarkers, CPD, beta(2)m, yielded receiver operating characteristic (ROC) value 0.99 distinguishing from beta(2)m MNDA GBP-2, reached an ROC 0.95 discriminating SLE. Conclusion. have successfully verified panel can discriminate If further validated those sicca but no disease, lead simple yet highly discriminatory clinical tool diagnosis SS.